Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Issued: Three Mullis patents, two (195 and 202) issued in July 1987 and the third (the 818 patent) in December 1989 Prosecuted by: Albert Halluin (now a partner in the Menlo Park, Calif., office of Washington, D.C.’s Howrey Simon Arnold & White) Litigated by: Lynn Pasahow (now of Palo Alto, Calif.’s Fenwick & West) Stanford University’s Cohen-Boyer patent on gene-splicing is the Michael Jordan of biotechnology patents. But unlike Mike, who is thinking of coming out of retirement, Cohen-Boyer can’t come back; it expired in December 1997. Cetus Corporation of Emeryville, Calif., hatched a dominant biotech patent perhaps most like Shaq. Cetus scientist Kary Mullis invented a method — known as polymerase chain reaction (PCR) — to take a small DNA section and make copies of it. Without PCR, forensic scientists, drug developers, and researchers would have a much harder time working with DNA. It also would have been impossible to map the human genome. E.I. du Pont de Nemours & Company had challenged the validity of two PCR patents (the 195 and 202 patents) in 1990. Cetus successfully defended those patents in San Francisco federal court.In 1992 Cetus sold the patents to F. Hoffman La-Roche Ltd. for $300 million. Hoffman La-Roche had built a healthy business licensing the technology for $100,000� to $500,000 in upfront fees, and 15 percent running royalties. The litigation is not over. Hoffman-La Roche sued Promega in 1992 for patent infringement in San Francisco federal court. Promega countersued in 1994. The patent in question was Mullis’ 818 patent for the Taq enzyme. Once the original DNA strand is unzipped, Taq helps glue together the multiple copies made of the original. In December 1999 federal judge Vaughn Walker invalidated that patent, finding that Cetus had committed fraud when the company obtained it. That ruling could jeopardize Hoffman La-Roche’s licensing strategy. But the company’s chief patent counsel Victor Lee maintains that the ruling is not devastating because the court invalidated only patent 818. Lee also says that enzymes other than Taq can be used in the PCR reaction. The U.S. Court of Appeals for the Federal Circuit heard the appeal in May. At press time, there was no decision.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.